<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675230</url>
  </required_header>
  <id_info>
    <org_study_id>XH-18-012</org_study_id>
    <nct_id>NCT03675230</nct_id>
  </id_info>
  <brief_title>Study of Tomotherapy HD in Medulloblastoma</brief_title>
  <official_title>Study of Tomotherapy HD in Medulloblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to improve local control and long-term survival in children with
      medulloblastoma, reduce the side effects of treatment and improve quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The technical advantages of Tomotherapy HD in the radiotherapy of children medulloblastoma
      (advantages in clinical operation and physics) were transformed into clinical advantages, and
      the possible mechanisms were explored.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QoL(quality of life)</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in quality of life were assessed by EORTC QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS (progression free survival)</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of therapy to the date of disease progression or death from any cause, whichever was first (according the criterion of RECIST 1.1 ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of therapy to death or last follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>3DCRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will be planned by 3DCRT to the treatment of the Medulloblastoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tomotherapy HD，TOMO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be planned by TOMO to the treatment of the Medulloblastoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tomotherapy HD</intervention_name>
    <description>Patients with Medulloblastoma receiving Tomotherapy</description>
    <arm_group_label>Tomotherapy HD，TOMO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3DCRT</intervention_name>
    <description>Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy</description>
    <arm_group_label>3DCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient was diagnosed as myeloblastoma by surgical pathology with definite
             pathological classification. MRI of the head and spinal cord before and after
             operation, with definite staging; Radiotherapy was performed within 28 days after
             surgery.

        Exclusion Criteria:

          -  Previous radiotherapy in the whole brain, whole spinal cord or primary focus;
             Postoperative radiotherapy for more than 28 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mawei jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chuanying zhu, MD</last_name>
    <phone>13795327309</phone>
    <email>zhuchuanying@xinhuamed.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Department of Radiation Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanying zhu, MD</last_name>
      <phone>862125076994</phone>
      <email>sdnanhai123@163.com</email>
    </contact>
    <investigator>
      <last_name>Mawei Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>September 16, 2018</last_update_submitted>
  <last_update_submitted_qc>September 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TOMO irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

